The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Madrigal Pharmaceuticals broke new ground earlier this year as its Rezdiffra became the first drug approved by the FDA to ...

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team ...

Novartis is investing more than $200 million to further bolster its radiotherapy infrastructure with a brand-new facility and ...

After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week.

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud ...

Astellas is closing a gene therapy manufacturing facility in South San Francisco. But, across the country, the company opened ...

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S.

After years of documentation and industry neglect, the World Health Organization (WHO) issued its first-ever guidance aimed ...